Decoy Therapeutics Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Decoy Therapeutics Inc. is a preclinical biopharmaceutical company focused on the discovery and development of peptide-conjugate therapeutics leveraging its IMP3ACT platform to streamline drug design, synthesis, and manufacturing for rapid antiviral and oncology programs. The company operates primarily in the United States and Europe, with a strategic emphasis on global access and scalable manufacturing capabilities to support rapid progression from preclinical stages toward clinical development. Decoy Therapeutics is headquartered in Paris, Île-de-France, France, and founders date to its rebranding and NASDAQ listing as Decoy Therapeutics (ticker DCOY) following the merger that transformed Salarius Pharmaceuticals into its current corporate structure in 2024. The firm maintains a portfolio approach, developing intranasal and systemic peptide-conjugate therapies designed to target respiratory viruses and cancer indications, with a core emphasis on building platform-based capabilities that enable rapid iteration, optimization, and potential future commercialization. Key activities include platform research using machine learning and AI-assisted design, peptide synthesis and conjugation manufacturing, and strategic collaborations to validate and scale its therapeutic candidates. The company’s business model centers on platform monetization through partnerships, joint development agreements, and potential future license or sale of developed assets, alongside ongoing investment in platform expansion, manufacturing scale-up, and pipeline advancement. Decoy Therapeutics places particular emphasis on global access initiatives, aiming to couple scientifically innovative antiviral and oncologic therapeutics with scalable production and distribution frameworks across multiple regions. The company’s current product focus encompasses pan-coronavirus antiviral programs, broad-acting antivirals for influenza and other respiratory pathogens, and peptide-drug conjugates for GI and oncology applications, with ongoing exploratory work to expand its therapeutic pipeline as it advances toward clinical filings and potential regulatory approvals.
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
Decoy Stock Rises After Announcing Up to $21 Million Private Placement Financing
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker
hVIVO signs consultancy deal with antiviral developer Decoy Therapeutics
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
Decoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug Development Transcript
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
ProMetic Life Sciences (OTCMKTS:PFSCF) vs. Decoy Therapeutics (NASDAQ:DCOY) Financial Analysis
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial